Moscow, 27 May, 2008 – OJSC Pharmstandard (LSE: PHST LI, RTS: PHST RU), the leading domestic pharmaceutical company in Russia and the third largest pharmaceutical company operating in Russia overall, invites its shareholders/holders to its annual general meeting of shareholders to be held at Petrovka str 11/20, Moscow, Russia, Marriot Aurora Hotel, “Stoleshniki” conference room at 10.00 am Moscow time on 27 June 2008 (hereinafter: the “AGM”). The record date for the AGM is 22 May 2008.
There are following key items will be discussed at the AGM:
1. Adoption of the financial statements for the year 2007 and allocation of profit and loses of the company based on year 2007 financial results.
2. Dividends for the year 2007.
3. Election of the Board of Directors.
4. Election of Audit Committee.
5. Appoint independent audit company for the year 2008.
6. Approve new redaction for the statute of OJSC “Pharmstandard”.
7. Approve regulations for the Management Board of OJSC “Pharmstandard”.
8. Approve regulations for the interested party transactions.
Enquiries:
OJSC Pharmstandard
Maxim Stetsyuk +7 495 970 0030
Email pr@pharmstd.ru
***
Notes to Editors:
Overview of Pharmstandard
Pharmstandard is the leading domestic pharmaceutical company in Russia and the third largest pharmaceutical company operating in Russia overall, by sales value. Pharmstandard is a leader of the biggest commercial segment of the Russian pharmaceutical segment. The Company develops, manufactures, markets and sells generic and, to a lesser extent, original pharmaceutical products in various formulations, primarily in Russia. Pharmstandard’s product portfolio includes market-leading brands (6 brands among top-20 best selling domestic brands in Russia), such as Arbidol® (antiviral for systemic use), Pentalgin® (analgesics), Terpincod® (cough and cold), Complivit® (vitamins), Codelac® (cough and cold) and Flucostat® (antifungal). In 2007, Arbidol® was the largest selling pharmaceutical product at the commercial segment of the Russian pharmaceutical market, according to pharmacy audit data by Pharmexpert.
Pharmstandard operates five manufacturing facilities in Russia and, with a production capacity of 1.3 billion packs as of December 31, 2007, has one of the largest production capacities among domestic pharmaceutical companies in Russia. The Company has invested approximately RUR2.4 billion in capital investments in its manufacturing facilities since the start of 2004. Pharmstandard’s flexible production capacity distinguishes it from its competitors by allowing it to quickly and efficiently adjust production based on input from its distributors and sales force.
In addition to its pharmaceutical business, the Company also develops, manufactures, markets and sells medical equipment, such as sterilizing and distilling machines, and disposable medical products.
| Back | Print out |
